Tanabe Pharma Corporation

This study tested a new vaccine called BK1310 in 370 healthy infants to see if it safely protects against several serious diseases: Hib, diphtheria, pertussis, tetanus, and polio. The vaccine was compared to existing vaccines. The goal was to check how well the infants' immune sy…

This study tested a new vaccine called BK1310 in 267 healthy infants to see if it protects against tetanus, diphtheria, pertussis, polio, and bacterial meningitis as well as existing vaccines. Infants received three doses, and researchers measured their immune responses. The goal…

This completed Phase 3 study tested a combined vaccine called BK1310 in 33 healthy infants. The vaccine aims to protect against diphtheria, tetanus, pertussis, polio, and Hib with a series of injections. Researchers measured antibody levels to see if the vaccine triggers a strong…

This study tested a booster dose of the DTaP vaccine (BK1301) in 446 adolescents aged 11-12 who had already received the standard childhood series. The goal was to confirm the vaccine boosts immunity against diphtheria, tetanus, and pertussis (whooping cough) safely. Results show…

This study tested a drug called Edaravone (MCI-186) in 36 people who had an acute ischemic stroke. The goal was to check the drug's safety and how the body processes it. Participants received either Edaravone or a placebo through an IV over 72 hours. The trial was completed, but …

This study looked at the safety of an oral form of edaravone for people with ALS, a nerve disease that weakens muscles. Fifteen patients who had already been in earlier edaravone studies took the drug for 10 days every two weeks. Researchers tracked side effects to see if the med…

This study tested an experimental drug called MT-6548 in 42 people in Japan who have anemia due to chronic kidney disease and are on peritoneal dialysis. The goal was to see if the drug can safely raise and maintain healthy red blood cell levels. Participants either switched from…

This study tested a new drug called MT-6548 against a standard treatment (darbepoetin alfa) for anemia in people on dialysis for chronic kidney disease. About 323 participants in Japan received either the new drug or the standard one to see if it worked as well at keeping hemoglo…

This phase 3 trial tested an oral drug called MT-6548 (vadadustat) against a standard injected drug (darbepoetin alfa) for anemia in people with chronic kidney disease who are not on dialysis. The study enrolled 304 participants in Japan to see if the oral drug is at least as goo…

This phase 3 trial tested an oral drug called vadadustat (MT-6548) in 24 Japanese adults on hemodialysis who had anemia due to chronic kidney disease. The goal was to see if the drug could raise and maintain healthy hemoglobin levels safely. Participants took the tablet daily, an…

This early study looked at a new drug, MT-2990, in 5 people with ANCA-associated vasculitis, a rare disease where the immune system attacks blood vessels. The goal was to see if the drug is safe and how it affects disease activity. Researchers measured changes in symptoms, imagin…

This early-stage study tested an experimental diabetes drug called TA-7284 in 24 people with type 2 diabetes, some with normal kidneys and some with moderate kidney impairment. Researchers measured how the drug moves through the body, how it affects blood sugar, and whether it is…

This study tested a higher dose (10 mg/kg every 8 weeks) of the drug TA-650 in 51 adults with psoriasis who had initially improved on the standard dose of Remicade but later lost that benefit. The goal was to see if the increased dose could again reduce skin symptoms. Participant…

This study tested a drug called MCI-196 in 245 adults on dialysis who have high phosphate levels, a common problem in advanced kidney disease. After a 4-week washout and 12-week dose adjustment, patients were randomly assigned to continue MCI-196 or switch to a placebo for 4 week…

This study tested the long-term safety of a drug called MCI-196 (Colestilan) in 116 adults with stage 5 chronic kidney disease who are on dialysis and have high phosphorus levels. Participants took flexible doses of the drug for 52 weeks. The main goal was to see how many side ef…

This study tested a drug called MCI-196 in 336 adults on dialysis with chronic kidney disease and high phosphorus levels. After a washout period, some patients received MCI-196 and others a placebo to see if the drug could safely lower phosphorus. The goal was to manage a common …

This Phase 2 trial tested an experimental oral drug called TA-7284 in 383 adults with type 2 diabetes. The drug works by helping the kidneys remove extra sugar through urine. Researchers compared four different doses of TA-7284 against a placebo to see how well it lowers blood su…

This study tested whether adding canagliflozin, a diabetes pill, to insulin therapy helps people with type 2 diabetes control their blood sugar better. 146 adults took either canagliflozin or a placebo for 16 weeks while continuing their insulin. Researchers measured changes in b…

This Phase 3 trial tested MCI-196, a drug that binds phosphorus and lowers cholesterol, in 642 adults on dialysis with chronic kidney disease. Participants received either MCI-196 or a placebo for 12 weeks. The goal was to see if the drug could safely reduce both serum phosphorus…

This study looked at whether adding canagliflozin to an existing GLP-1 medication is safe and helpful for people with type 2 diabetes. 71 adults took the combination for 52 weeks. Researchers tracked side effects, blood sugar levels, weight, and blood pressure. The goal was to se…

This study tested an experimental drug called TA-7284 in 272 adults with type 2 diabetes. Participants took either a low dose, high dose, or a placebo pill daily for 24 weeks. The goal was to see if the drug safely lowers blood sugar levels (measured by A1C) compared to placebo.

This study tested an experimental drug called TA-7284 in 61 adults with type 2 diabetes. Participants took different doses (25 to 400 mg) or a placebo once daily for 15 days. The main goal was to check safety and how the drug moves through the body, with a secondary look at its e…

This study looked at the long-term safety and effectiveness of adding canagliflozin to insulin therapy in adults with type 2 diabetes. A total of 139 people who had completed a previous 16-week study took part. Researchers tracked side effects, blood sugar control, and weight cha…

This large Phase 3 trial tested whether AST-120, a spherical carbon adsorbent taken as a pill, can slow the progression of chronic kidney disease. Over 1,000 adults with moderate to severe kidney disease were randomly assigned to receive AST-120 or a placebo, in addition to their…

This study tested a new medication, TA-7284, in 1,299 adults with type 2 diabetes over 52 weeks. The goal was to see if the drug is safe and helps control blood sugar when used alone or with other diabetes medicines. Results focused on side effects, blood sugar levels, and weight…

This Phase 3 trial tested whether AST-120, a spherical carbon adsorbent taken as a powder, can slow the progression of chronic kidney disease. Over 1,000 adults with moderate to severe kidney disease received either AST-120 or a placebo alongside their usual care. The main goal w…

This study tested whether adding teneligliptin to canagliflozin helps Japanese adults with type 2 diabetes who still have high blood sugar despite taking canagliflozin alone. Over 24 weeks, 154 participants took both drugs once daily. The main goal was to see if the combination l…

This study tested a clot-dissolving medicine called alteplase in 58 people who had a stroke caused by a blocked artery. The goal was to see how well it reopened blocked brain arteries and improved patients' ability to function three months later. The results were compared to exis…

This study tested a drug called teneligliptin in 254 Chinese adults with type 2 diabetes. Half received the drug and half received a placebo for 24 weeks. The main goal was to see if teneligliptin lowers blood sugar levels (HbA1c) better than a placebo. Researchers also checked f…

This study looked at whether a higher dose (10 mg/kg) of the drug infliximab (TA-650) could help people with Crohn's disease who were not getting enough benefit from the standard dose (5 mg/kg). The 39 participants received the higher dose every 8 weeks. The main goal was to see …

This study tested the long-term safety of a drug called MCI-196 in 632 adults with chronic kidney disease on dialysis who have high phosphorus levels. Participants took the drug for up to 52 weeks to see how it affected their phosphorus and cholesterol. The goal was to help contr…

This study tested a new drug called MP-424 (Telaprevir) added to the standard two-drug therapy for hepatitis C. It involved 189 adults with genotype 1 hepatitis C who had never been treated before. The goal was to see if the triple combination could clear the virus from the blood…

This Phase 3 trial tested the drug edaravone (MCI-186) in 206 people with ALS. Participants received daily intravenous infusions for 14 days, followed by a rest period, repeated over 24 weeks. The goal was to see if edaravone could slow the decline in physical function compared t…

This study tested three doses of argatroban, a blood thinner, in 140 patients undergoing elective heart stent procedures. It compared argatroban to the standard blood thinner heparin, both given with clopidogrel and aspirin. The goal was to see how well argatroban prevents blood …

This study tested a new drug called MCI-196 to lower bad cholesterol in people with advanced chronic kidney disease who are on dialysis. About 260 adults took part, comparing MCI-196 to a standard statin (simvastatin) and a placebo. The goal was to see if MCI-196 works better tha…

This phase 2 study tested MP-424 (Telaprevir) in 15 people with genotype 1b hepatitis C who had not been treated with interferon before. Participants took three 250 mg tablets every 8 hours for 24 weeks. The main goal was to see if the virus became undetectable 24 weeks after tre…

This study tested four different doses of a new drug called MP-513 in 448 adults with type 2 diabetes who were already taking metformin. The goal was to see which dose works best and is safe for lowering blood sugar over 24 weeks, with an extension up to 52 weeks. Participants to…

This study tested whether canagliflozin, a diabetes drug, can slow kidney decline in 308 Japanese patients with diabetic nephropathy. Participants took either the drug or a placebo daily for about two years. The main goal was to see if fewer people on the drug had a 30% drop in k…

This study tested whether adding canagliflozin to the existing diabetes drug teneligliptin helps Japanese adults with type 2 diabetes who still have high blood sugar. Over 24 weeks, researchers measured changes in HbA1c (a key blood sugar marker), fasting glucose, and body weight…

This study looked at the long-term safety and tolerability of the drug MP-214 in 254 people with schizophrenia. Participants had already completed an earlier trial and continued taking MP-214 at flexible doses. The main goal was to track side effects over time.

This study looked at how well the drug argatroban works in 20 adults with a condition called heparin-induced thrombocytopenia Type II, where the blood thinner heparin causes low platelets and raises clot risk. Participants received argatroban to prevent new or worsening blood clo…

This phase 3 trial tested a drug called telaprevir (MP-424) combined with two standard hepatitis C drugs (peginterferon and ribavirin) in 10 people with genotype 2 hepatitis C who had not responded to previous treatment. The goal was to see if this combination could clear the vir…

This study tested a drug called TA-650 in 21 children with moderate to severe ulcerative colitis, a condition causing inflammation and sores in the colon. The goal was to see if the drug could reduce disease activity and improve symptoms. Children received the drug by infusion at…

This phase 3 study tested whether adding teneligliptin to metformin helps Chinese adults with type 2 diabetes control their blood sugar better than metformin alone. 247 participants took either teneligliptin or a placebo for 24 weeks. The main goal was to see if HbA1c (a measure …

This study tested a once-daily combination of two diabetes drugs (Teneligliptin and Canagliflozin) in 153 Japanese adults with type 2 diabetes whose blood sugar was not well controlled on Teneligliptin alone. Participants took the combo pill for 52 weeks to see if it was safe and…

This study tested a triple-drug combination—telaprevir, peginterferon, and ribavirin—in 109 adults with genotype 1 hepatitis C whose infection returned after previous treatment. The goal was to see if the new regimen could clear the virus from the blood 24 weeks after treatment e…

This completed Phase 3 trial tested an experimental drug called MP-424, combined with two standard hepatitis C medications (pegylated interferon and ribavirin), in 54 adults with genotype 1 hepatitis C. Participants were either new to treatment or had relapsed after previous ther…

This study tested whether increasing the dose of infliximab (a drug that blocks inflammation) helps people with active rheumatoid arthritis who did not improve enough with methotrexate alone. 327 adults received one of three doses (3, 6, or 10 mg/kg) by IV infusion over nearly a …

This study tested the drug edaravone (MCI-186) in 181 people with ALS, a progressive nerve disease. Participants received either edaravone or a placebo through IV infusions over 24 weeks. The goal was to see if edaravone could slow the decline in physical function. Results sugges…

This completed study tested an experimental drug called MP-214 in 512 people with schizophrenia. Participants took either a daily dose of MP-214 (3, 6, or 9 mg), an existing antipsychotic (risperidone), or a placebo for six weeks. The main goal was to see if MP-214 reduces schizo…

This study tested a drug called TA-650 (also known as infliximab) in 14 children with moderate to severe Crohn's disease. The drug was given as an IV infusion to reduce inflammation and control symptoms. The goal was to see if it could lower disease activity scores and improve th…

This study looked at a new drug called MP-214 in 38 adults with schizophrenia. The goal was to see how safe the drug is, how the body processes it, and whether it helps control symptoms. Participants took the drug for 12 weeks, and researchers monitored side effects and drug leve…

This study tested the long-term safety and effectiveness of a new daily pill called MP-214 in 125 people with chronic or elderly schizophrenia. Participants took either MP-214 or the existing drug risperidone for several weeks. The goal was to see if MP-214 is a safe and tolerabl…

This study tested a new drug called MP-424 (telaprevir) added to standard therapy (peginterferon and ribavirin) for people with genotype 2 hepatitis C whose infection came back after previous treatment. The goal was to see if the combination could clear the virus for good. The tr…

This study tested a lower dose (0.6 mg/kg) of the clot-busting drug alteplase in 103 Japanese patients who had a stroke within the previous 3 hours. The goal was to see if this dose was both safe and effective for this population. Results focused on how many patients had little t…

This study tested a drug called MCI-186 in 137 people with ALS, a nerve disease that weakens muscles over time. The goal was to see if the drug could slow down the disease compared to a placebo over 24 weeks. The main measure was a scale of daily function. The trial did not show …

This study tested a drug called TA-650 in 31 children with Kawasaki disease whose fever did not go away after standard IVIG treatment. The goal was to see if TA-650 could bring down the fever faster and prevent damage to heart arteries compared to another immunoglobulin treatment…

This study compared two medications, edaravone and sodium ozagrel, for treating acute ischemic stroke. Researchers wanted to see which drug helped more people recover with little or no disability three months after treatment. The study included 401 adults who started treatment wi…

This study tested a new drug called MP-424 combined with two standard medicines (interferon beta and ribavirin) in 74 adults with chronic hepatitis C (genotype 1 or 2). Participants either had never been treated before or had previously received interferon-based therapy. The main…

This study tested whether adding teneligliptin to standard sulfonylurea therapy improves blood sugar control in 194 Japanese adults with type 2 diabetes. Participants received either teneligliptin or a placebo for 12 weeks, followed by an open-label extension for up to 52 weeks. …

This early-phase trial tested a new hepatitis C drug called telaprevir (MP-424) combined with two standard medications (peginterferon and ribavirin) in 20 people with genotype 1b hepatitis C. The main goals were to check safety and how the drug moves through the body. Researchers…

This study tested whether higher doses of ursodeoxycholic acid (UDCA) could better lower liver enzymes in 596 adults with chronic hepatitis C. Participants received 150, 600, or 900 mg of UDCA daily for 24 weeks. The main goal was to see if the higher doses were more effective an…

This study tested three different doses of MP-214 (cariprazine) in 34 adults with schizophrenia. The goal was to check safety, how the drug moves through the body, and whether it helps control symptoms. Participants took the drug once daily for 14 days, starting low and increasin…

This study tested whether adding an experimental drug called MP-435 to standard methotrexate treatment helps people with rheumatoid arthritis who don't get enough relief from methotrexate alone. 112 adults took either MP-435 or a placebo (dummy pill) plus their usual methotrexate…

This study looked at the long-term safety and effectiveness of an investigational drug called MP-214 in 42 adults with schizophrenia who were already taking other antipsychotic medications. The main goal was to see how many people had side effects. The study was completed and hel…

This study tested a new drug called MP-424 combined with two standard medications (peginterferon alfa-2b and ribavirin) in 32 adults with genotype 1 hepatitis C who had not responded to earlier treatment. The main goal was to see if the virus could be cleared from the blood 24 we…

This study tested an experimental drug, MCI-196, in 183 people with type 2 diabetes to see if it could help control blood sugar and improve cholesterol levels. Participants took the drug or a placebo for 12 weeks. The goal was to measure changes in blood glucose and HbA1c, a key …

This study tested a new diabetes drug called teneligliptin (MP-513) combined with pioglitazone in 204 Japanese adults with type 2 diabetes. Participants took the combination for 12 weeks, then continued for up to a year. The main goal was to see if it lowered blood sugar levels (…

This study tested the drug TA-650 (infliximab) in 18 people with Behcet's disease who had hard-to-treat lesions. The drug was given by IV every few weeks for nearly a year. The goal was to see if symptoms and signs of inflammation could be completely controlled. The trial is comp…

This study tested the long-term safety and blood sugar control of the drug MP-513 (Teneligliptin) in 240 Japanese adults with type 2 diabetes. Some participants took MP-513 alone, while others took it together with another diabetes medicine called glimepiride. The study lasted 52…

This early-phase study tested MP-424 (telaprevir) in 10 patients with chronic hepatitis C genotype 1b. Participants took three 250 mg tablets every 8 hours for 12 weeks. The main goals were to check safety, how the drug moves through the body, and how it affects hepatitis C virus…

This study tested a drug called MCI-186 in 25 people with advanced ALS (severity grade III) to see if it could slow the disease. Participants received either the drug or a placebo daily through an IV for 24 weeks. The main goal was to measure changes in daily function and safety,…

This study tested the long-term safety of MP-513 (Teneligliptin) in 462 Japanese adults with type 2 diabetes. Participants took the drug alone or with other oral diabetes medicines for 52 weeks. The main goal was to track side effects, and researchers also measured blood sugar co…

This phase 2 study tested a new drug called teneligliptin (MP-513) in 324 Japanese adults with type 2 diabetes. Participants took one of three doses of the drug or a placebo daily for 12 weeks. The main goal was to see how well the drug lowered blood sugar levels (HbA1c) and to c…

This study tested a new diabetes medicine called MP-513 (Teneligliptin) in 203 Japanese adults with type 2 diabetes. The goal was to see if the drug safely lowers blood sugar levels over 12 weeks. Participants took either the drug or a placebo pill, and researchers measured chang…

This study tested whether adding the diabetes pill teneligliptin to insulin helps people with type 2 diabetes control their blood sugar better. 148 Japanese adults who were already on a stable insulin dose took either teneligliptin or a placebo for 16 weeks, with an extension up …

This study tested a new drug called MP-513 in 99 Japanese adults with type 2 diabetes. The goal was to see how well it controls blood sugar levels over 4 weeks. Participants took the drug and had their blood sugar measured after meals and throughout the day.

This study tested a new vaccine called MT-2301, which protects against Haemophilus influenzae type b (Hib), given together with the standard DPT-IPV vaccine (which protects against diphtheria, pertussis, tetanus, and polio). The trial involved 154 healthy infants aged 2 to 7 mont…

This study tested whether the drug TAU-284 (bepotastine besilate) can reduce sneezing, runny nose, and congestion in children aged 7 to 15 with perennial allergic rhinitis (year-round nasal allergies). In a double-blind, placebo-controlled design, 473 children took either the dru…

This study tested whether a new oral medicine called TAU-284 (bepotastine besilate) can reduce itching in children aged 7 to 15 with atopic dermatitis (eczema). Over 300 children took either TAU-284 or an older medicine (ketotifen) twice daily for several weeks. The main goal was…

This study tested a medicine called TAU-284 in 490 children aged 7 to 15 who have year-round nasal allergies. The goal was to see if it reduces sneezing, runny nose, and congestion better than a placebo. The trial was completed and focused on symptom relief, not a cure.

This study tested a drug called MT-5547 (fasinumab) in 626 Japanese adults with moderate to severe osteoarthritis pain in the knee or hip. Participants received either the drug or a placebo injection for 16 weeks. The goal was to see if the drug reduces pain and improves daily fu…

This study tested a once-daily drug called MT-5199 in 256 adults with tardive dyskinesia, a condition causing uncontrollable movements. The goal was to see if the drug could reduce these movements safely. Participants had mental health conditions like schizophrenia or bipolar dis…

This study tested the long-term safety and effectiveness of TAU-284 (bepotastine besilate) in 58 children aged 7 to 15 with perennial allergic rhinitis (year-round nasal allergies). Over 12 weeks, researchers tracked side effects and changes in sneezing, runny nose, and congestio…

This study tested an experimental drug called MT-8554 in 61 adults with painful diabetic peripheral neuropathy, a common complication of diabetes causing nerve pain. The goal was to see if the drug could safely reduce pain compared to a placebo. Participants took the drug or plac…

This study tested a drug called MT-8554 (Elismetrep) in 156 adults with painful diabetic peripheral neuropathy. The goal was to see if it reduces pain better than a placebo over 12 weeks. Participants took either the drug or a placebo capsule, and pain was measured using a 0-10 s…

This early-stage study tested a new drug called MT-8554 in 24 women who have frequent hot flashes due to menopause or breast cancer treatment. The main goal was to check the drug's safety and how the body processes it. Researchers also looked at whether it could reduce the number…

This early-stage study tested a single dose of the investigational drug MT-2990 in 75 adults with seasonal allergic rhinitis triggered by Japanese cedar pollen. The main goals were to check the drug's safety, how the body processes it, and whether it can reduce allergy symptoms w…

This early-stage study looked at how a single dose of oral edaravone moves through the bodies of 9 Japanese adults with ALS. The main goal was to measure drug levels in the blood and urine, not to test if it helps symptoms. Researchers also tracked any side effects. The study is …

This study tested whether MCI-186, an experimental drug, changes the heart's electrical activity (QT interval) in 27 healthy adult men. Participants received a low dose, a high dose, and a placebo on separate days. The goal was to see if the drug could cause dangerous heart rhyth…

This study looked at how the drug edaravone enters the body when given as a liquid by mouth or through a nasogastric tube (a thin tube that goes through the nose to the stomach). It involved 36 healthy Japanese adults aged 20 to 45. The main goal was to measure drug levels in the…

This study looked at how the drug MCI-186 (also called edaravone) behaves in people with mild or moderate liver impairment compared to those with healthy livers. Twenty-two participants received a single dose of the drug. The goal was to see if liver problems affect how the drug …

This early-stage study looked at how the body handles a single dose of oral edaravone in 6 Japanese ALS patients who have a feeding tube (gastrostomy). The goal was to measure drug levels in the blood and urine, not to test if it works. No treatment benefit was evaluated.

This early-phase trial tested an oral form of edaravone in 74 healthy adult males to see how safe it is and how the body processes it. Participants received single or multiple doses of the drug or a placebo. The study is complete and focused on gathering basic safety and drug-lev…

This study looked at how eating different types of meals affects the way the body absorbs oral edaravone, a medication used for ALS. Sixteen healthy Japanese adults took the drug under five different dietary conditions, including fasting. The goal was to understand how food chang…

This completed Phase 1 study looked at how an oral form of edaravone interacts with three other drugs (rosuvastatin, sildenafil, and furosemide) in healthy adult men. It also compared how Japanese and Caucasian men process edaravone. The goal was to gather safety and drug-level d…

This study looked at how the drug MCI-186 is handled by the body in people with mild or moderate kidney impairment compared to those with normal kidneys. Thirty adults received a single dose of the drug, and researchers measured its levels in the blood. The goal was to understand…

This completed Phase 1 study looked at how the drug MCI-186 (Edaravone) is processed in the body of people with severe liver impairment compared to healthy individuals. Twelve participants received a single intravenous dose. The goal was to measure drug levels and safety, not to …

This study looked at how iron supplements change the way the body handles a drug called MT-6548. It involved 61 healthy Japanese men and measured drug levels in the blood. The goal was to gather safety and drug interaction data, not to treat any disease.

This early-phase trial tested the safety and how the body processes the drug MT-7117 (dersimelagon) in 40 healthy Chinese adults aged 18 to 55. Participants received either the drug or a placebo, and researchers measured drug levels in the blood and monitored for side effects. Th…

This completed Phase 1 trial looked at how colestilan, a drug for high phosphate levels in kidney disease, affects the body's processing of candesartan, a blood pressure medication. Eighteen healthy men took candesartan alone or with colestilan at different times. The goal was to…

This study tested whether an oral suspension of edaravone works as well as the intravenous (IV) form in 42 healthy Japanese adults. Participants received a single dose of each version, and researchers measured drug levels in the blood to compare them. The goal was to see if the o…

This study looked at how a new drug called MT-8554 changes the way the body processes two common cholesterol-lowering medicines, simvastatin and rosuvastatin. Twenty-eight healthy men took the statins alone and then with MT-8554 to see if their blood levels changed. The goal was …

This early-stage study tested a single dose of MT-8554, a new drug being developed for pain, in 20 healthy men. Researchers measured how the drug affects the body's response to a cold-induced pain test and checked for safety. The goal was to gather initial data, not to treat any …

This early-phase trial tested the safety and tolerability of a new drug called MT-8554 in 135 healthy adults. Participants received either the drug or a placebo, and researchers monitored vital signs, heart activity, lab results, and side effects. The study did not aim to treat a…